Weill Cornell Cardiovascular Outcomes Research Group (CORG) Division of Cardiology Department of Medicine Weill Cornell Medicine New York Presbyterian Hospital New York NY.
Dalio Institute of Cardiovascular Imaging Department of Radiology Weill Cornell Medicine New York Presbyterian Hospital New York NY.
J Am Heart Assoc. 2020 Jun 2;9(11):e015503. doi: 10.1161/JAHA.119.015503. Epub 2020 May 29.
Background Readmission after ST-segment-elevation myocardial infarction (STEMI) poses an enormous economic burden to the US healthcare system. There are limited data on the association between length of hospital stay (LOS), readmission rate, and overall costs in patients who underwent primary percutaneous coronary intervention for STEMI. Methods and Results All STEMI hospitalizations were selected in the Nationwide Readmissions Database from 2010 to 2014. From the patients who underwent primary percutaneous coronary intervention, we examined the 30-day outcomes including readmission, mortality, reinfarction, repeat revascularization, and hospital charges/costs according to LOS (1-2, 3, 4, 5, and >5 days) stratified by infarct locations. The 30-day readmission rate after percutaneous coronary intervention for STEMI was 12.0% in the anterior wall (AW) STEMI group and 9.9% in the non-AW STEMI group. Patients with a very short LOS (1-2 days) were readmitted less frequently than those with a longer LOS regardless of infarct locations. However, patients with a very short LOS had significantly increased 30-day readmission mortality versus an LOS of 3 days (hazard ratio, 1.91; CI, 1.16-3.16 [=0.01]) only in the AW STEMI group. Total costs (index admission+readmission) were the lowest in the very short LOS cohort in both the AW STEMI group (<0.001) and the non-AW STEMI group (<0.001). Conclusions For patients who underwent primary percutaneous coronary intervention for STEMI, a very short LOS was associated with significantly lower 30-day readmission and lower cumulative cost. However, a very short LOS was associated with higher 30-day mortality compared with at least a 3-day stay in the AW STEMI cohort.
ST 段抬高型心肌梗死(STEMI)再入院给美国医疗体系带来了巨大的经济负担。关于接受直接经皮冠状动脉介入治疗(PCI)的 STEMI 患者的住院时间(LOS)、再入院率和总费用之间的关系,数据有限。
从 2010 年至 2014 年,我们在全国再入院数据库中选择了所有 STEMI 住院患者。在接受直接 PCI 的患者中,我们根据梗死部位,按 LOS(1-2、3、4、5 和>5 天)分层,检查了 30 天结局,包括再入院、死亡率、再梗死、再次血运重建和住院费用/成本。在前壁 STEMI 组中,STEMI 患者接受 PCI 治疗后 30 天再入院率为 12.0%,非前壁 STEMI 组为 9.9%。无论梗死部位如何,LOS 较短(1-2 天)的患者再入院频率低于 LOS 较长的患者。然而,在前壁 STEMI 组中,LOS 非常短(1-2 天)的患者与 LOS 为 3 天的患者相比,30 天再入院死亡率显著增加(危险比,1.91;95%CI,1.16-3.16[=0.01])。在前壁 STEMI 组(<0.001)和非前壁 STEMI 组(<0.001),LOS 非常短的患者的总费用(指数入院+再入院)最低。
对于接受直接 PCI 治疗的 STEMI 患者,LOS 非常短与 30 天再入院率显著降低和累计成本降低相关。然而,在前壁 STEMI 队列中,与至少 3 天的住院相比,LOS 非常短与 30 天死亡率较高相关。